280 related articles for article (PubMed ID: 12852722)
1. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
Becker A; van der Does FE; van Hinsbergh VW; Heine RJ; Bouter LM; Stehouwer CD
Neth J Med; 2003 Apr; 61(4):129-36. PubMed ID: 12852722
[TBL] [Abstract][Full Text] [Related]
2. Fibrinogen and von Willebrand factor in IDDM: relationships to lipid vascular risk factors, blood pressure, glycaemic control and urinary albumin excretion rate: the EURODIAB IDDM Complications Study.
Greaves M; Malia RG; Goodfellow K; Mattock M; Stevens LK; Stephenson JM; Fuller JH
Diabetologia; 1997 Jun; 40(6):698-705. PubMed ID: 9222650
[TBL] [Abstract][Full Text] [Related]
3. Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.
Hermann LS; Ranstam J; Vaaler S; Melander A
Diabetes Obes Metab; 1999 Jul; 1(4):227-32. PubMed ID: 11228758
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control.
Tan CE; Chew LS; Chio LF; Tai ES; Lim HS; Lim SC; Jayakumar L; Eng HK; Packard CJ
Diabetes Res Clin Pract; 2001 Feb; 51(2):107-14. PubMed ID: 11165690
[TBL] [Abstract][Full Text] [Related]
5. Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects--evidence against a modulating role for insulin.
Mohamed-Ali V; Gould MM; Gillies S; Goubet S; Yudkin JS; Haines AP
Diabetologia; 1995 Sep; 38(9):1110-6. PubMed ID: 8591827
[TBL] [Abstract][Full Text] [Related]
6. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?
Scott R; Lintott CJ; Zimmet P; Campbell L; Bowen K; Welborn T
Diabetes Res Clin Pract; 1999 Mar; 43(3):179-85. PubMed ID: 10369427
[TBL] [Abstract][Full Text] [Related]
7. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
8. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55).
Davis TM; Cull CA; Holman RR;
Diabetes Care; 2001 Jul; 24(7):1167-74. PubMed ID: 11423497
[TBL] [Abstract][Full Text] [Related]
10. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.
Jain SK; Nagi DK; Slavin BM; Lumb PJ; Yudkin JS
Diabet Med; 1993; 10(1):27-32. PubMed ID: 8435984
[TBL] [Abstract][Full Text] [Related]
11. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
13. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects.
Yudkin JS; Panahloo A; Stehouwer C; Emeis JJ; Bulmer K; Mohamed-Ali V; Denver AE
Diabetologia; 2000 Sep; 43(9):1099-106. PubMed ID: 11043855
[TBL] [Abstract][Full Text] [Related]
14. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Chatterjee S; Majumder A; Ray S
Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients.
Ahmad Khan H
Acta Diabetol; 2007 Dec; 44(4):193-200. PubMed ID: 17786383
[TBL] [Abstract][Full Text] [Related]
16. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.
Abraira C; Colwell JA; Nuttall FQ; Sawin CT; Nagel NJ; Comstock JP; Emanuele NV; Levin SR; Henderson W; Lee HS
Diabetes Care; 1995 Aug; 18(8):1113-23. PubMed ID: 7587846
[TBL] [Abstract][Full Text] [Related]
17. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
[TBL] [Abstract][Full Text] [Related]
18. Classical cardiovascular risk factors in Trinidadian patients with type 2 diabetes mellitus are not influenced by the level of plasma glycaemia.
Ezenwaka CE; Offiah NV
West Indian Med J; 2001 Dec; 50(4):288-93. PubMed ID: 11993019
[TBL] [Abstract][Full Text] [Related]
19. Improvements in glycaemic control and cholesterol concentrations associated with the Quality and Outcomes Framework: a regional 2-year audit of diabetes care in the UK.
Oluwatowoju I; Abu E; Wild SH; Byrne CD
Diabet Med; 2010 Mar; 27(3):354-9. PubMed ID: 20536500
[TBL] [Abstract][Full Text] [Related]
20. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
